VIVS — VivoSim Labs Income Statement
0.000.00%
- $3.17m
- $2.26m
- $0.11m
Annual income statement for VivoSim Labs, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.2 | 0 | 1.5 | 0.37 | 0.109 |
Cost of Revenue | |||||
Gross Profit | 1.87 | 0 | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 23.7 | 16.8 | 13 | 18.1 | 15.2 |
Operating Profit | -21.5 | -16.8 | -11.5 | -17.7 | -15.1 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -18.7 | -16.8 | -11.4 | -17.3 | -14.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -18.7 | -16.8 | -11.4 | -17.3 | -14.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -18.7 | -16.8 | -11.4 | -17.3 | -14.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18.7 | -16.8 | -11.4 | -17.3 | -14.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.63 | -2.17 | -1.32 | -1.98 | -1.6 |